FEATURE ARTICLES
Regulatory changes, space/footprint constraints and expanding automation garnered more votes than the other challenges. Let’s explore these challenges, and see how the industry is tackling them as we move into 2026.
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
- 5 FDA Approval Categories In 2025
- A 2025 Pharma Look Back and Look Forward: Editor Style
- 2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
- A Deeper Look At Pharma's Structural Supply Chain Vulnerability
PHARMA ONLINE WHITE PAPERS
-
![Supply Chain - Getty- 1159559071]( "If You Can't Win The Game, Change It")
If You Can't Win The Game, Change ItExplore how eData sharing is used in the biopharma market, enabling standardized, collaborative supply chains that reduce risks and enhance visibility while improving capacity planning.
-
Oligonucleotide Synthesis: Scale-Up Made Simple10/16/2024
Scaling oligonucleotide synthesis isn't as straightforward as it seems. Explore key challenges, critical process parameters, and solutions for a smooth scale-up.
-
Leveraging Flow Chemistry1/22/2026
Discover how continuous processing cuts waste, improves efficiency, and supports safer, scalable reactions while helping teams meet sustainability goals and speed development.
-
Project Management: Sphere Of Influence10/21/2024
The project manager's sphere of influence extends beyond the project team, encompassing the organization, industry, and professional discipline.
-
Maximize Your Laboratory Efficiency10/20/2025
Gain insight into how labs can boost productivity by reducing downtime, minimizing errors, and increasing walk-away time through real-time insights and analytics.
-
Understanding Viral Clearance During Anion-Exchange Chromatography3/26/2024
A design of experiments (DoE) study examined the anion-exchange process in general and to draw possible correlations between such properties and overall viral clearance capability.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Part I: Defining The Dye Ingress Operating Window
- High-Throughput IgG Quantification Assay For Cell Line Development
- Achieving Licensing For A Healthcare Solution
- Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals
- Revolutionizing Viral Infectious Disease Research And Drug Discovery
NEWSLETTER ARCHIVE
- 02.09.26 -- Next‑Gen Inspection Tech Driving Safer, Smarter Pharma Production
- 02.07.26 -- Oral Solid Dose Manufacturing Product Showcase
- 02.06.26 -- Biological Indicator Testing – Meeting Regulatory Demands With Confidence
- 02.05.26 -- STREAM Edition: Contamination Control Strategies For Drug Manufacturers
- 02.03.26 -- Novo's Path To The First GLP-1 Weight Loss Pill
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
KeyPlants AB Expands Production Capacity With New Facility In Götene, Sweden2/9/2026
KeyPlants AB is strengthening its global production capacity through a significant expansion into Götene, Sweden. In response to a recently secured large-scale order and an increasingly strong project pipeline, the company is establishing operations at the Götenehus industrial site under a four-year lease agreement with Forshem Fastigheter.
-
Is A Cybersecurity Boom On The Horizon? KPMG Survey Shows Surge In Cybersecurity Investment As AI Threats Redefine Risk2/5/2026
A cybersecurity boom appears imminent as businesses invest to defend against a new generation of sophisticated, AI-driven threats. According to the 2025 KPMG Cybersecurity Survey, a staggering 99% of security leaders plan to increase their cybersecurity budgets over the next two to three years, signaling that cybersecurity is no longer just a priority but a critical business imperative.
-
Eli Lilly To Build New $3.5B Injectable Drug Manufacturing Site Supporting GLP-1 Therapies In Pennsylvania2/2/2026
Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania.
-
Halo Pharma To Become A Stand-Alone Drug Product Contract Development And Manufacturing Organization (CDMO)1/27/2026
Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses to Siegfried.
